Drugs / CHF5633
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01651637 | Oct 2012 → Jan 2015 | respiratory distress syndrome in premature infants | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02452476 | Jan 2016 → May 2018 | newborn respiratory distress syndrome | Chiesi Farmaceutici S.p.A. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF 5633 | “synthetic surfactant (CHF 5633) in comparison to porcine surfactant” NCT02452476 ↗ |
| Modality | Other / unclassified | “CHF5633 (Chiesi Farmaceutici S.p.A., Parma, Italy) is the first fully synthetic surfactant enriched by peptide analogues of two human surfactant proteins.” PMID 28465315 ↗ May 2017 |
| Route | Other | “endotracheal surfactant administration within 24 hours from birth” NCT02452476 ↗ |